4 February 2022 - Tecentriq (atezolizumab) is the first and only cancer immunotherapy approved for non-small cell lung cancer in the adjuvant setting.

Roche Canada is pleased to announce that on 14 January 2022, Health Canada has authorised Tecentriq (atezolizumab) as monotherapy for adjuvant treatment following complete resection and no progression after platinum-based adjuvant chemotherapy for adult patients with stage II to IIIA non-small cell lung cancer whose tumours have PD-L1 expression on ≥ 50% of tumour cells.

Read Roche press release